Translational insight into statin-induced muscle toxicity: From cell culture to clinical studies

Translational Research

Volumn 164, Issue 2, 2014, Pages 85-109

  Taha, Dhiaa A ^a   De Moor, Cornelia H ^a   Barrett, David A ^a   Gershkovich, Pavel ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Abbreviations; ABCG2; adenosine triphosphate binding cassette G2; CK; CoA; coenzyme A; creatine kinase; electromyographic; EMG; F PP; farnesyl pyrophosphate; FDA; Food and Drug Administration; G PP; geranylgeranyl pyrophosphate; HMG; hydroxy methylglutaryl; lactate dehydrogenase; LDH; LDL C; low density lipoprotein cholesterol; MDR; MRP; multidrug resistance gene; multidrug resistance associated protein; OATP; organic anion transporting polypeptide; PDE; phosphodiester; RD; rhabdomyosarcoma; single nucleotide polymorphism; SLCO; SNP; solute carrier organic anion gene; terminal deoxynucleotidyl transferase mediated 2 deoxyuridine 5 triphosphate nick end labeling; TUNEL; UGT; uridine diphosphate glucuronosyltransferase

Indexed keywords

AMIODARONE; ATORVASTATIN; CERIVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; DANAZOL; DILTIAZEM; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; FLUCONAZOLE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIBEFRADIL; NEFAZODONE; PITAVASTATIN; PRAVASTATIN; RITONAVIR; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS; VERAPAMIL;

APOPTOSIS; ARTICLE; ASSAY; CASPASE ASSAY; COMORBIDITY; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; FEMALE; FOOD DRUG INTERACTION; GENDER; GENETIC RISK; GENETIC VARIABILITY; GRAPEFRUIT JUICE; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; INCIDENCE; LIPID DIET; LIPOPHILICITY; LOW DRUG DOSE; MEDICATION COMPLIANCE; MEMBRANE DAMAGE; META ANALYSIS (TOPIC); MITOCHONDRIAL MEMBRANE POTENTIAL; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE METABOLISM; MUSCLE NECROSIS; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; MYOTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHABDOMYOLYSIS; RISK FACTOR; SKELETAL MUSCLE; SYSTEMATIC REVIEW (TOPIC); TOXIC LIGHT ASSAY; TOXICITY; TRANSLATIONAL RESEARCH; TRYPAN BLUE ASSAY;

CELLS, CULTURED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE CELLS; MUSCULAR DISEASES;

EID: 84904819494     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2014.01.013     Document Type: Review

References (165)

1. P. Gazzerro, M.C. Proto, and G. Gangemi et al. Pharmacological actions of statins: a critical appraisal in the management of cancer Pharmacol Rev 64 2012 102 146
2. Y. Shitara, and Y. Sugiyama Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions Pharmacol Ther 112 2006 71 105 (Pubitemid 44301483)
3. J. Sidaway, Y. Wang, and A.M. Marsden et al. Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy Xenobiotica 39 2009 90 98
4. P.H. Chong, J.D. Seeger, and C. Franklin Clinically relevant differences between the statins: implications for therapeutic selection Am J Med 111 2001 390 400 (Pubitemid 32913673)
5. V. Tandon, G. Bano, V. Khajuria, A. Parihar, and S. Gupta Pleiotropic effects of statins Indian J Pharmacol 37 2005 77 85 (Pubitemid 40545240)
6. A. Endo The origin of the statins Atheroscler Suppl 5 2004 125 130
7. Q. Feng, R.A. Wilke, and T.M. Baye Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions Pharmacogenomics 13 2012 579 594
8. R. Arora, M. Liebo, and F. Maldonado Statin-induced myopathy: the two faces of Janus J Cardiovasc Pharmacol Ther 11 2006 105 112 (Pubitemid 44449099)
9. M. Evans, and A. Rees The myotoxicity of statins Curr Opin Lipidol 13 2002 415 420 (Pubitemid 34831945)
10. U. Christians, W. Jacobsen, and L.C. Floren Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 80 1998 1 34 (Pubitemid 28498199)
11. G.B. Mancini, S. Baker, and J. Bergeron et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference Can J Cardiol 27 2011 635 662
12. L.S. Rallidis, K. Fountoulaki, and M. Anastasiou-Nana Managing the underestimated risk of statin-associated myopathy Int J Cardiol 159 2012 169 176
13. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Begaud Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414 (Pubitemid 43228152)
14. J.M. McKenney, M.H. Davidson, T.A. Jacobson, and J.R. Guyton Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 97 2006 89C 94C
15. T. Klopstock Drug-induced myopathies Curr Opin Neurol 21 2008 590 595
16. T.R. Joy, and R.A. Hegele Narrative review: statin-related myopathy Ann Intern Med 150 2009 858 868
17. M. Tomaszewski, K.M. Stepien, J. Tomaszewska, and S.J. Czuczwar Statin-induced myopathies Pharmacol Rep 63 2011 859 866
18. C. Vaklavas, Y.S. Chatzizisis, A. Ziakas, C. Zamboulis, and G.D. Giannoglouc Molecular basis of statin-associated myopathy Atherosclerosis 202 2009 18 28
19. R.C. Pasternak, S.C. Smith, C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, and C. Lenfant ACC/AHA/NHLBI clinical advisory on the use and safety of statins J Am Coll Cardiol 40 2002 567 572 (Pubitemid 34833176)
20. P.D. Thompson, P. Clarkson, and R.H. Karas Statin-associated myopathy JAMA 289 2003 1681 1690 (Pubitemid 37430274)
21. T. Menge, H.P. Hartung, and O. Stuve Statins: a cure-all for the brain? Nat Rev Neurosci 6 2005 325 331
22. A.J. Dirks, and K.M. Jones Statin-induced apoptosis and skeletal myopathy Am J Physiol Cell Physiol 291 2006 C1208 C1212
23. O.P. Flint, B.A. Masters, R.E. Gregg, and S.K. Durham Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro Toxicol Appl Pharmacol 145 1997 91 98 (Pubitemid 27294774)
24. L. Marcoff, and P.D. Thompson The role of coenzyme Q10 in statin-associated myopathy: a systematic review J Am Coll Cardiol 49 2007 2231 2237 (Pubitemid 46856819)
25. M. Turunen, J. Olsson, and G. Dallner Metabolism and function of coenzyme Q Biochim Biophys Acta 1660 2004 171 199 (Pubitemid 38125244)
26. L. Miles, M.V. Miles, and P.H. Tang et al. Muscle coenzyme Q: a potential test for mitochondrial activity and redox status Pediatr Neurol 32 2005 318 324 (Pubitemid 40626747)
27. R.A. Willis, K. Folkers, J.L. Tucker, C.Q. Ye, L.J. Xia, and H. Tamagawa Lovastatin decreases coenzyme Q levels in rats Proc Natl Acad Sci U S A 87 1990 8928 8930 (Pubitemid 120007622)
28. K. Folkers, P. Langsjoen, and R. Willis et al. Lovastatin decreases coenzyme Q levels in humans Proc Natl Acad Sci U S A 87 1990 8931 8934 (Pubitemid 120007623)
29. G. Rousseau, C. Desrosiers, and F. Varin A comparison of the effects of lovastatin and pravastatin on ubiquinone tissue levels in rats Curr Ther Res 59 1998 666 679 (Pubitemid 28446992)
30. E. von Keutz, and G. Schluter Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor Am J Cardiol 82 1998 11J 17J (Pubitemid 28429254)
31. 2+-release system J Pharmacol Exp Ther 321 2007 626 634 (Pubitemid 46624499)
32. P. Sirvent, J. Mercier, G. Vassort, and A. Lacampagne Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle Biochem Biophys Res Commun 329 2005 1067 1075 (Pubitemid 40341384)
33. J. Bhuiyan, and D.W. Seccombe The effects of 3-hydroxy-3-methylglutaryl- CoA reductase inhibition on tissue levels of carnitine and carnitine acyltransferase activity in the rabbit Lipids 31 1996 867 870 (Pubitemid 26275329)
34. R.L. Wortmann Dose related statin myopathy: is it an issue? Cleve Clin J Med 72 2005 751 753
35. M. Kobayashi, Y. Otsuka, S. Itagaki, T. Hirano, and K. Iseki Inhibitory effects of statins on human monocarboxylate transporter 4 Int J Pharm 317 2006 19 25 (Pubitemid 43866340)
36. M.C. Wilson, V.N. Jackson, and C. Heddle et al. Lactic acid efflux from white skeletal muscle is catalyzed by the monocarboxylate transporter isoform MCT3 J Biol Chem 273 1998 15920 15926 (Pubitemid 28311355)
37. J.E. Manning Fox, D. Meredith, and A.P. Halestrap Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle J Physiol 529 2000 285 293 (Pubitemid 32040847)
38. M. Kobayashi, I. Fujita, S. Itagaki, T. Hirano, and K. Iseki Transport mechanism for L-lactic acid in human myocytes using human prototypic embryonal rhabdomyosarcoma cell line (RD cells) Biol Pharm Bull 28 2005 1197 1201 (Pubitemid 41327585)
39. M. Kobayashi, K. Hidaka, and I. Chisaki et al. Effects of acidification and alkalinization agent on statins-induced muscle toxicity Yakugaku Zasshi 132 2012 609 615
40. M. Kobayashi, F. Kaido, T. Kagawa, S. Itagaki, T. Hirano, and K. Iseki Preventive effects of bicarbonate on cerivastatin-induced apoptosis Int J Pharm 341 2007 181 188 (Pubitemid 47088121)
41. A.P. Tuckow, S.J. Jefferson, S.R. Kimball, and L.S. Jefferson Simvastatin represses protein synthesis in the muscle-derived C2C12 cell line with a concomitant reduction in eukaryotic initiation factor 2B expression Am J Physiol Endocrinol Metab 300 2011 E564 E570
42. J. Hanai, P. Cao, and P. Tanksale et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity J Clin Invest 117 2007 3940 3951 (Pubitemid 350224103)
43. M. Sandri, C. Sandri, and A. Gilbert et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy Cell 117 2004 399 412 (Pubitemid 38534545)
44. P. Cao, J. Hanai, P. Tanksale, S. Imamura, V.P. Sukhatme, and S.H. Lecker Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect FASEB J 23 2009 2844 2854
45. B.A. Masters, M.J. Palmoski, O.P. Flint, R.E. Gregg, D. Wangiverson, and S.K. Durham In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes Toxicol Appl Pharmacol 131 1995 163 174
46. P. Kaufmann, M. Torok, A. Zahno, K.M. Waldhauser, K. Brecht, and S. Kraehenbuehl Toxicity of statins on rat skeletal muscle mitochondria Cell Mol Life Sci 63 2006 2415 2425 (Pubitemid 44653050)
47. M. Itagaki, A. Takaguri, S. Kano, S. Kaneta, K. Ichihara, and K. Satoh Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats J Pharmacol Sci 109 2009 94 101
48. I.B. Skottheim, A. Gedde-Dahl, S. Hejazifar, K. Hoel, and A. Asbery Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro Eur J Pharm Sci 33 2008 317 325
49. Z. Darzynkiewicz, G. Juan, X. Li, W. Gorczyca, T. Murakami, and F. Traganos Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis) Cytometry 27 1997 1 20 (Pubitemid 27059777)
50. K. Sakamoto, T. Honda, S. Yokoya, S. Waguri, and J. Kimura Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers FASEB J 21 2007 4087 4094 (Pubitemid 350232365)
51. J. van Meerloo, G.J. Kaspers, and J. Cloos Cell sensitivity assays: the MTT assay Methods Mol Biol 731 2011 237 245
52. E. Vega-Avila, and M.K. Pugsley An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells Proc West Pharmacol Soc 54 2011 10 14
53. M. Kobayashi, T. Kagawa, R. Takano, S. Itagaki, T. Hirano, and K. Iseki Effect of medium pH on the cytotoxicity of hydrophilic statins J Pharm Pharm Sci 10 2007 332 339 (Pubitemid 350055591)
54. M. Kobayashi, I. Chisaki, and K. Narumi et al. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins Life Sci 82 2008 969 975
55. M. Kobayashi, T. Kagawa, K. Narumi, S. Itagaki, T. Hirano, and K. Iseki Bicarbonate supplementation as a preventive way in statins-induced muscle damage J Pharm Pharm Sci 11 2008 1 8
56. K. Sakamoto, H. Mikami, and J. Kimura Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres Br J Pharmacol 154 2008 1482 1490
57. K. Sakamoto, I. Wada, and J. Kimura Inhibition of Rab1 GTPase and endoplasmic reticulum-to-Golgi trafficking underlies statin's toxicity in rat skeletal myofibers J Pharmacol Exp Ther 338 2011 62 69
58. A. Gadbut, A. Caruso, and J. Galper Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin J Mol Cell Cardiol 27 1995 2397 2402
59. P.J. Mullen, B. Luscher, H. Scharnagl, S. Kraehenuehl, and K. Brecht Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy Biochem Pharmacol 79 2010 1200 1209
60. T.E. Johnson, X.H. Zhang, and K.B. Bleicher et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone Toxicol Appl Pharmacol 200 2004 237 250 (Pubitemid 39422423)
61. J. Sacher, L. Weigl, M. Werner, C. Szegedi, and M. Hohenegger Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells J Pharmacol Exp Ther 314 2005 1032 1041 (Pubitemid 41205966)
62. D.T. Loo In situ detection of apoptosis by the TUNEL assay: an overview of techniques Methods Mol Biol 682 2011 3 13
63. P.J. Mullen, A. Zahno, and P. Lindinger et al. Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt Biochim Biophys Acta 1813 2011 2079 2087
64. P. Sirvent, S. Bordenave, and M. Vermaelen et al. Simvastatin induces impairment in skeletal muscle while heart is protected Biochem Biophys Res Commun 338 2005 1426 1434 (Pubitemid 41608410)
65. P. Sirvent, J. Mercier, and A. Lacampagne New insights into mechanisms of statin-associated myotoxicity Curr Opin Pharmacol 8 2008 333 338
66. S. Pierno, A. De Luca, and D. Tricarico et al. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers J Pharmacol Exp Ther 275 1995 1490 1496 (Pubitemid 26129941)
67. S. Pierno, A. De Luca, A. Liantonio, C. Camerino, and D.C. Camerino Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle Eur J Pharmacol 364 1999 43 48 (Pubitemid 29015785)
68. S. Pierno, M.P. Didonna, and V. Cippone et al. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study Br J Pharmacol 149 2006 909 919 (Pubitemid 44851715)
69. F.R. Westwood, A. Bigley, K. Randall, A.M. Marsden, and R.C. Scott Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity Toxicol Pathol 33 2005 246 257 (Pubitemid 40381453)
70. F.R. Westwood, R.C. Scott, A.M. Marsden, A. Bigley, and K. Randall Rosuvastatin: characterization of induced myopathy in the rat Toxicol Pathol 36 2008 345 352 (Pubitemid 351534480)
71. J.L. Seachrist, C.M. Loi, M.G. Evans, K.A. Criswell, and C.E. Rothwell Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity Toxicol Sci 88 2005 551 561 (Pubitemid 41672163)
72. W.H. Schaefer, J.W. Lawrence, and A.F. Loughlin et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats Toxicol Appl Pharmacol 194 2004 10 23 (Pubitemid 38064437)
73. J.E. Mallinson, D. Constantin-Teodosiu, J. Sidaway, F.R. Westwood, and P.L. Greenhaff Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy J Physiol 587 2009 219 230
74. J. Sugatani, S. Sadamitsu, and M. Kurosawa et al. Nutritional status affects fluvastatin-induced hepatotoxicity and myopathy in rats Drug Metab Dispos 38 2010 1655 1664
75. J.D. Vassallo, E.B. Janovitz, D.M. Wescott, C. Chadwick, L.J. Lowe-Krentz, and L.D. Lehman-McKeeman Biomarkers of drug-induced skeletal muscle injury in the rat: troponin I and myoglobin Toxicol Sci 111 2009 402 412
76. K. Nakahara, M. Kuriyama, and Y. Sonoda et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study Toxicol Appl Pharmacol 152 1998 99 106 (Pubitemid 28498678)
77. M. Fukami, N. Maeda, and J. Fukushige et al. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits Res Exp Med (Berl) 193 1993 263 273 (Pubitemid 23319581)
78. K. Nakahara, M. Kuriyama, and H. Yoshidome et al. Experimental simvastatin-induced myopathy in rabbits J Neurol Sci 113 1992 114 117
79. S. Pierno, G.M. Camerino, and V. Cippone et al. Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression Br J Pharmacol 156 2009 1206 1215
80. 31-phosphorus magnetic resonance spectroscopy in patients on statin medications Muscle Nerve 43 2011 76 81
81. M.G. Mohaupt, R.H. Karas, and E.B. Babiychuk et al. Association between statin-associated myopathy and skeletal muscle damage CMAJ 181 2009 E11 E18
82. S.A. Peters, R. Kley, M. Tegenthoff, M. Vorgerd, V. Nicolas, and C.M. Heyer MRI in lipid-lowering agent-associated myopathy: a retrospective review of 21 cases AJR Am J Roentgenol 194 2010 W323 W328
83. S. Sathasivam, and B. Lecky Statin induced myopathy BMJ 337 2008 a2286
84. C.R. Harper, and T.A. Jacobson Evidence-based management of statin myopathy Curr Atheroscler Rep 12 2010 322 330
85. W.W. Campbell Statin myopathy: the iceberg or its tip? Muscle Nerve 34 2006 387 390 (Pubitemid 44506705)
86. S. Guis, J.P. Mattei, and D. Bendahan Toxic myopathies Joint Bone Spine 80 2013 231 233
87. R.L. Talbert Safety issues with statin therapy J Am Pharm Assoc 46 2006 479 488
88. P.M. Clarkson, A.K. Kearns, P. Rouzier, R. Rubin, and P.D. Thompson Serum creatine kinase levels and renal function measures in exertional muscle damage Med Sci Sports Exerc 38 2006 623 627
89. S.L. Di Stasi, T.D. MacLeod, J.D. Winters, and S.A. Binder-Macleod Effects of statins on skeletal muscle: a perspective for physical therapists Phys Ther 90 2010 1530 1542
90. S. Paganoni, and A. Amato Electrodiagnostic evaluation of myopathies Phys Med Rehabil Clin North Am 24 2013 193 207
91. M. Troseid, O.A. Henriksen, and S. Lindal Statin-associated myopathy with normal creatine kinase levels: case report from a Norwegian family APMIS 113 2005 635 637 (Pubitemid 41577161)
92. H. Sinzinger, P. Schmid, and J. O'Grady Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment Atherosclerosis 143 1999 459 460 (Pubitemid 29166930)
93. A. Kashani, C.O. Phillips, and J.M. Foody et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials Circulation 114 2006 2788 2797 (Pubitemid 46018281)
94. R. Benghozi, M. Bortolini, Y. Jia, J.L. Isaacsohn, A.J. Troendle, and L. Gonasun Frequency of creatine kinase elevation during treatment with fluvastatin Am J Cardiol 89 2002 231 233 (Pubitemid 34132919)
95. J.M. Slade, M.C. Delano, and R.A. Meyer Elevated skeletal muscle phosphodiesters in adults using statin medications Muscle Nerve 34 2006 782 784 (Pubitemid 44877564)
96. J.A. Strommen, J.S. Johns, and C.T. Kim et al. Neuromuscular rehabilitation and electrodiagnosis: 3. Diseases of muscles and neuromuscular junction Arch Phys Med Rehabil 86 2005 S18 S27
97. T. Huynh, D. Cordato, and F. Yang et al. HMG CoA reductase-inhibitor- related myopathy and the influence of drug interactions Intern Med J 32 2002 486 490 (Pubitemid 35015337)
98. P.D. Thompson, P.M. Clarkson, and R.S. Rosenson An assessment of statin safety by muscle experts Am J Cardiol 97 2006 69C 76C
99. L. Christopher-Stine, L.A. Casciola-Rosen, G. Hong, T. Chung, A.M. Corse, and A.L. Mammen A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy Arthritis Rheum 62 2010 2757 2766
100. M.A. Pfeffer, A. Keech, and F.M. Sacks et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project Circulation 105 2002 2341 2346 (Pubitemid 34556383)
101. P.S. Phillips, and R.H. Haas Statin-associated myopathy with normal creatine kinase levels: in response Ann Intern Med 138 2003 1008 1009
102. P.S. Phillips, R.H. Haas, and S. Bannykh et al. Statin-associated myopathy with normal creatine kinase levels Ann Intern Med 137 2002 581 585
103. G.D. Vladutiu, Z. Simmons, and P.J. Isackson et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies Muscle Nerve 34 2006 153 162 (Pubitemid 44167798)
104. K. Kuncova, M. Sedlackova, and J. Vencovsky et al. Inflammatory myopathy associated with statins: report of three cases Mod Rheumatol 24 2014 366 371
105. P. Mohassel, and A.L. Mammen Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies Muscle Nerve 48 2013 477 483
106. A.A. Carvalho, U.W. Lima, and R.A. Valiente Statin and fibrate associated myopathy: study of eight patients Arq Neuropsiquiatr 62 2004 257 261 (Pubitemid 38715309)
107. A. Draeger, K. Monastyrskaya, and M. Mohaupt et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia J Pathol 210 2006 94 102 (Pubitemid 44288185)
108. M.J. Knauer, B.L. Urquhart, and H.E. Meyer zu Schwabedissen et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins Circ Res 106 2010 297 306
109. M. Silva, M.L. Matthews, and C. Jarvis et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy Clin Ther 29 2007 253 260 (Pubitemid 46661859)
110. D.L. McClure, R.J. Valuck, M. Glanz, J.R. Murphy, and J.E. Hokanson Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population J Clin Epidemiol 60 2007 812 818 (Pubitemid 47007672)
111. J. Wlodarczyk, D. Sullivan, and M. Smith Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials Am J Cardiol 102 2008 1654 1662
112. K.M. Dale, C.M. White, N.N. Henyan, J. Kluger, and C.I. Coleman Impact of statin dosing intensity on transaminase and creatine kinase Am J Med 120 2007 706 712 (Pubitemid 47189656)
113. B.A. Hamelin, and J. Turgeon Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors Trends Pharmacol Sci 19 1998 26 37 (Pubitemid 28094090)
114. Y.S. Chatzizisis, K.C. Koskinas, G. Misirli, C. Vaklavas, A. Hatzitolios, and G.D. Giannoglou Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment Drug Saf 33 2010 171 187
115. D.J. Yang, and L.S. Hwang Study on the conversion of three natural statins from lactone forms to their corresponding hydroxy acid forms and their determination in Pu-Erh tea J Chromatogr A 1119 2006 277 284 (Pubitemid 43831894)
116. C. Chen, R.J. Mireles, and S.D. Campbell et al. Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1 Drug Metab Dispos 33 2005 537 546 (Pubitemid 40393197)
117. S. Beretta, C. Pastori, and G. Sala et al. Acute lipophilicity-dependent effect of intravascular simvastatin in the early phase of focal cerebral ischemia Neuropharmacology 60 2011 878 885
118. M. Hoffmann, and M. Nowosielski DFT study on hydroxy acid-lactone interconversion of statins: the case of atorvastatin Org Biomol Chem 6 2008 3527 3531
119. T. Grabarkiewicz, P. Grobelny, M. Hoffmann, and J. Mielcarek DFT study on hydroxy acid-lactone interconversion of statins: the case of fluvastatin Org Biomol Chem 4 2006 4299 4306 (Pubitemid 44748042)
120. P.J. Neuvonen, M. Niemi, and J.T. Backman Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Clin Pharmacol Ther 80 2006 565 581 (Pubitemid 44908269)
121. A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paoletti, and F. Bernini New insights into the pharmacodynamic and pharmacokinetic properties of statins Pharmacol Ther 84 1999 413 428
122. S.K. Baker, and M.A. Tarnopolsky Statin myopathies: pathophysiologic and clinical perspectives Clin Invest Med 24 2001 258 272 (Pubitemid 33097304)
123. M. Law, and A.R. Rudnicka Statin safety: a systematic review Am J Cardiol 97 2006 52C 60C
124. M. Igel, T. Sudhop, and K. von Bergmann Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) Eur J Clin Pharmacol 57 2001 357 364 (Pubitemid 33787186)
125. C.G. Rowan, S.M. Brunelli, and J. Munson et al. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network Pharmacoepidemiol Drug Saf 21 2012 494 506
126. V. Fischer, L. Johanson, and F. Heitz et al. The 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions Drug Metab Dispos 27 1999 410 416 (Pubitemid 29114251)
127. R. Nirogi, K. Mudigonda, and V. Kandikere Chromatography-mass spectrometry methods for the quantitation of statins in biological samples J Pharm Biomed Anal 44 2007 379 387 (Pubitemid 46887638)
128. P.J. Neuvonen Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics Curr Opin Invest Drugs 11 2010 323 332
129. M.S. Kostapanos, H.J. Milionis, and M.S. Elisaf Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia Am J Cardiovasc Drugs 10 2010 11 28
130. M.V. Varma, C.J. Rotter, and J. Chupka et al. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1 Mol Pharmacol 8 2011 1303 1313
131. C. Olbricht, C. Wanner, and T. Eisenhauer et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses Clin Pharmacol Ther 62 1997 311 321 (Pubitemid 27417797)
132. C. Rowan, A.D. Brinker, and P. Nourjah et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors Pharmacoepidemiol Drug Saf 18 2009 301 309
133. T. Sakaeda, H. Fujino, and C. Komoto et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport Pharm Res 23 2006 506 512
134. C.W. Holtzman, B.S. Wiggins, and S.A. Spinler Role of P-glycoprotein in statin drug interactions Pharmacotherapy 26 2006 1601 1607 (Pubitemid 44704473)
135. C. Chen, J. Lin, T. Smolarek, and L. Tremaine P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in MDR1A/B knockout and wild-type mice Drug Metab Dispos 35 2007 1725 1729 (Pubitemid 47481596)
136. K. Bogman, A.K. Peyer, M. Torok, E. Kusters, and J. Drewe HMG-CoA reductase inhibitors and P-glycoprotein modulation Br J Pharmacol 132 2001 1183 1192 (Pubitemid 32234701)
137. S. Bhardwaj, S. Selvarajah, and E.B. Schneider Muscular effects of statins in the elderly female: a review Clin Interv Aging 8 2013 47 59
138. S. Hilmer, and D. Gnjidic Statins in older adults Aust Prescr 36 2013 79 82
139. S. Schech, D. Graham, and J. Staffa et al. Risk factors for statin-associated rhabdomyolysis Pharmacoepidemiol Drug Saf 16 2007 352 358 (Pubitemid 46431698)
140. C. Stancu, and A. Sima Statins: mechanism of action and effects J Cell Mol Med 5 2001 378 387
141. R.S. Rosenson Current overview of statin-induced myopathy Am J Med 116 2004 408 416 (Pubitemid 38299486)
142. M.J. Cziraky, V.J. Willey, and J.M. McKenney et al. Statin safety: an assessment using an administrative claims database Am J Cardiol 97 2006 61C 68C
143. B.A. Parker, and P.D. Thompson Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes Exerc Sport Sci Rev 40 2012 188 194
144. S. Mehrotra, K. Kim, and D. Liebovitz Myopathy prevalence in statin treated patients with comorbidities and combination therapies J Am Coll Cardiol 59 2012 E274
145. P. Gershkovich, D. Shtainer, and A. Hoffman The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins Int J Pharm 333 2007 1 4 (Pubitemid 46283283)
146. W.N. Charman Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts J Pharm Sci 89 2000 967 978
147. J.C. Hopewell, A. Offer, and S. Parish et al. Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE Eur Heart J 33 2012 445
148. W.J. Kostis, J.Q. Cheng, J.M. Dobrzynski, J. Cabrera, and J.B. Kostis Meta-analysis of statin effects in women versus men J Am Coll Cardiol 59 2012 572 582
149. E. Lee, S. Ryan, and B. Birmingham et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment Clin Pharmacol Ther 78 2005 330 341 (Pubitemid 41393668)
150. J. Hippisley-Cox, and C. Coupland Individualising the risks of statins in men and women in England and Wales: population-based cohort study Heart 96 2010 939 947
151. A. Vermes, and I. Vermes Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors Am J Cardiovasc Drugs 4 2004 247 255 (Pubitemid 39206618)
152. A.B. Mulder, H.J. van Lijf, and M.A. Bon et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin Clin Pharmacol Ther 70 2001 546 551 (Pubitemid 34008412)
153. T.N. Frudakis, M.J. Thomas, S.N. Ginjupalli, B. Handelin, R. Gabriel, and H.J. Gomez CYP2D6*4 polymorphism is associated with statin-induced muscle effects Pharmacogenet Genomics 17 2007 695 707 (Pubitemid 47263065)
154. R. Kaspera, S.B. Naraharisetti, and B. Tamraz et al. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis Pharmacogenet Genomics 20 2010 619 629
155. S. Riedmaier, K. Klein, and U. Hofmann et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo Clin Pharmacol Ther 87 2010 65 73
156. M. Hermann, M.P. Bogsrud, and E. Molden et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy Clin Pharmacol Ther 79 2006 532 539 (Pubitemid 43833450)
157. Q. Ma, and A.Y. Lu Pharmacogenetics, pharmacogenomics, and individualized medicine Pharmacol Rev 63 2011 437 459
158. P. Couvert, P. Giral, and S. Dejager et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy Pharmacogenomics 9 2008 1217 1227
159. A. Ghatak, O. Faheem, and P.D. Thompson The genetics of statin-induced myopathy Atherosclerosis 210 2010 337 343
160. M. Niemi Transporter pharmacogenetics and statin toxicity Clin Pharmacol Ther 87 2010 130 133
161. G.T. Generaux, F.M. Bonomo, M. Johnson, and K.M.M. Doan Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins Xenobiotica 41 2011 639 651
162. SEARCH Collaborative Group E. Link, S. Parish, and J. Armitage et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study N Engl J Med 359 2008 789 799
163. I. Ieiri, S. Suwannakul, and K. Maeda et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers Clin Pharmacol Ther 82 2007 541 547 (Pubitemid 47622520)
164. Y. Kameyama, K. Yamashita, K. Kobayashi, M. Hosokawa, and K. Chiba Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells Pharmacogenet Genomics 15 2005 513 522 (Pubitemid 41017600)
165. M. Fiegenbaum, F.R. da Silveira, and C.R. Van der Sand et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment Clin Pharmacol Ther 78 2005 551 558 (Pubitemid 41698910)